Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5354676 | 0.86 | KMT2A (0.53) | LMNAALDH1A1MEN1KMT2ACYP2C9 | |
| SCHEMBL3096849 | 0.85 | SMN1; SMN2 (0.59) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5365608 | 0.82 | KMT2A (0.61) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1106964 | 0.82 | HDAC1 (0.62) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7431069 | 0.81 | LMNA (0.52) | LMNAALDH1A1MEN1KMT2ACYP2C9 | |
| SCHEMBL5363086 | 0.81 | ALDH1A1 (0.63) | LMNAALDH1A1MAPTKMT2APLOD2 | |
| SCHEMBL14880128 | 0.78 | ROCK2 (0.63) | LMNAALDH1A1CYP2C9CYP2C19EPHX2 | |
| SCHEMBL10822708 | 0.78 | ROCK2 (0.63) | LMNAALDH1A1CYP2C9CYP2C19EPHX2 | |
| SCHEMBL29748479 | 0.78 | LMNA (0.60) | LMNAALDH1A1MEN1KMT2APLOD2 | |
| SCHEMBL2794824 | 0.78 | LMNA (0.60) | LMNAALDH1A1MEN1KMT2APLOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | claimed |
| US-6608094-B2 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-08-19 | — | — | US | claimed |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2007-07-19 | — | — | US | disclosed |
| US-7223777-B2 | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2007-05-29 | — | — | US | disclosed |
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | disclosed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | disclosed |
| US-6608094-B2 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. (IN) | 2003-08-19 | — | — | US | disclosed |
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | disclosed |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-03-06 | — | — | US | disclosed |
| US-20030032660-A1 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. | 2003-02-13 | — | — | US | disclosed |
| EP-1243581-A1 | Pyridinium compounds useful for the treatment of AGE-related diseases | Torrent Pharmaceuticals Ltd (IN) | 2002-09-25 | — | — | EP | disclosed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, GLA, RBP1 | LMNA 635/4885ALDH1A1 769/4885MAPT 2944/4885 |
| US-20030032660-A1 | Breaking preformed AGE | AGER, GPX1, RBP1 | LMNA 802/4885ALDH1A1 1451/4885MAPT 2142/4885 |
| US-20030045554-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | LMNA 641/4885ALDH1A1 132/4885MAPT 4105/4885 |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | PNPO, PRDX5, PLPBP | LMNA 812/4885ALDH1A1 662/4885MAPT 3306/4885 |
| US-20070167493-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof | AGER, GLA, F12 | LMNA 480/4885ALDH1A1 226/4885MAPT 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.